Madrigal Pharmaceuticals (MDGL) Announces $300+ Million in Financing Events to Advance Resmetirom Program
Madrigal Pharmaceuticals, Inc. (MDGL) announced that it has raised $259 million in gross equity (or $255 million in net proceeds) from equity securities issuances and an additional $50 million in liquidity commitments
